Hereditary Angioedema with Normal C1 Inhibitor: Update on Evaluation and Treatment

Magerl M., Germenis A.E., Maas C., Maurer M.

dc.creator	Magerl M., Germenis A.E., Maas C., Maurer M.	en
dc.date.accessioned	2023-01-31T08:55:38Z
dc.date.available	2023-01-31T08:55:38Z
dc.date.issued	2017
dc.identifier	10.1016/j.iac.2017.04.004
dc.identifier.issn	08898561
dc.identifier.uri	http://hdl.handle.net/11615/76061
dc.description.abstract	A new form of hereditary angioedema (HAE) was identified in the year 2000. Its clinical appearance resembles HAE types I and II, which are caused by mutations that result in a deficiency of C1 inhibitor (C1-INH). In patients with the new form of HAE, C1-INH plasma levels and function values are normal, so it's termed HAE with normal C1-INH (HAE-nC1). HAE-nC1, in a subgroup of patients, is thought to be caused by mutations that affect the F12 gene. The diagnosis of HAE-nC1 is based on history and clinical criteria. There are no licensed drugs with proven treatment effects for HAE-nC1. © 2017 Elsevier Inc.	en
dc.language.iso	en	en
dc.source	Immunology and Allergy Clinics of North America	en
dc.source.uri	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85021836423&doi=10.1016%2fj.iac.2017.04.004&partnerID=40&md5=55159388b12b4a28d8ad87fc53b39873
dc.subject	bradykinin	en
dc.subject	complement component C1s inhibitor	en
dc.subject	ecallantide	en
dc.subject	icatibant	en
dc.subject	tranexamic acid	en
dc.subject	blood clotting factor 12	en
dc.subject	bradykinin	en
dc.subject	complement component C1s inhibitor	en
dc.subject	plasmin	en
dc.subject	protein binding	en
dc.subject	SERPING1 protein, human	en
dc.subject	angioneurotic edema	en
dc.subject	clinical feature	en
dc.subject	differential diagnosis	en
dc.subject	evaluation study	en
dc.subject	genetics	en
dc.subject	human	en
dc.subject	long term care	en
dc.subject	pathophysiology	en
dc.subject	priority journal	en
dc.subject	prophylaxis	en
dc.subject	Review	en
dc.subject	short course therapy	en
dc.subject	angioneurotic edema	en
dc.subject	disease management	en
dc.subject	genetic predisposition	en
dc.subject	metabolism	en
dc.subject	mutation	en
dc.subject	phenotype	en
dc.subject	premedication	en
dc.subject	signal transduction	en
dc.subject	treatment outcome	en
dc.subject	Angioedemas, Hereditary	en
dc.subject	Bradykinin	en
dc.subject	Complement C1 Inhibitor Protein	en
dc.subject	Diagnosis, Differential	en
dc.subject	Disease Management	en
dc.subject	Factor XII	en
dc.subject	Fibrinolysin	en
dc.subject	Genetic Predisposition to Disease	en
dc.subject	Humans	en
dc.subject	Mutation	en
dc.subject	Phenotype	en
dc.subject	Premedication	en
dc.subject	Protein Binding	en
dc.subject	Signal Transduction	en
dc.subject	Treatment Outcome	en
dc.subject	W.B. Saunders	en
dc.title	Hereditary Angioedema with Normal C1 Inhibitor: Update on Evaluation and Treatment	en
dc.type	other	en

Αρχεία σε αυτό το τεκμήριο

Αρχεία	Μέγεθος	Τύπος	Προβολή
Δεν υπάρχουν αρχεία που να σχετίζονται με αυτό το τεκμήριο.

Αυτό το τεκμήριο εμφανίζεται στις ακόλουθες συλλογές

Δημοσιεύσεις σε περιοδικά, συνέδρια, κεφάλαια βιβλίων κλπ. [19705]

Εμφάνιση απλής εγγραφής